Montelukast Tillomed (Montelukast Sodium)

Montelukast Sodium, the active ingredient in Montelukast Tillomed, is a leukotriene receptor antagonist presented as an oral dosage form for systemic use. It is used to manage asthma, allergic rhinitis, and exercise‑induced bronchoconstriction in both adult and pediatric patients.

GNH USA supplies Montelukast Tillomed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast Tillomed acts on leukotriene pathways to control inflammatory airway conditions. - Asthma: reduces frequency of asthma attacks and improves lung function. - Allergic rhinitis: alleviates nasal congestion, sneezing and itchy eyes. - Exercise‑induced bronchoconstriction: prevents airway narrowing during physical activity.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate pain in the head. - Abdominal pain: discomfort or cramps in the stomach area. - Cough: occasional irritation of the throat. - Dyspepsia: indigestion or feeling of fullness. - Nausea: sensation of needing to vomit. - Fatigue: feeling unusually tired.

Serious or Rare Side Effects: - Allergic reactions: rash, angioedema, or hives. - Neuropsychiatric events: mood changes, anxiety, or suicidal thoughts. - Hepatic enzyme elevation: abnormal liver function tests. - Stevens‑Johnson syndrome: severe skin blistering. - Eosinophilic pneumonia: rare lung inflammation. - Anaphylaxis: life‑threatening allergic response.

Montelukast should be used with awareness of specific safety considerations. - Pregnancy: consult a healthcare provider before use. - Breastfeeding: discuss potential risks with a physician. - Age: use with caution in children under 12 years. - Drug interactions: review all concomitant medications. - Neuropsychiatric monitoring: report any mood or behavioral changes. - Store at ambient temperature: keep in the original container, protect from moisture.

Montelukast may interact with several medicines; monitoring is advised.

Major Interactions (Avoid): - Ritonavir: may increase montelukast plasma concentrations. - Phenobarbital: may reduce montelukast effectiveness. - Carbamazepine: may lower montelukast levels.

Moderate Interactions (Monitor Closely): - Warfarin: possible alteration of INR values. - Theophylline: may enhance side‑effect profile. - Fluconazole: could increase montelukast exposure.